Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00416624 · ClinicalTrials.gov registry record · Phase 2
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
NCT00416624: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00416624 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 239 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00416624, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
Study Summary
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer. PURPOSE: This randomized clinical trial is studying four different schedules of epoetin alfa or darbepoetin alfa to compare how well they work in treating patients with anemia caused by chemotherapy.
Interventions
- PROCEDURE quality-of-life assessment
- PROCEDURE fatigue assessment and management
- DRUG darbepoetin alfa
- DRUG epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00416624
The ClinicalTrials.gov registry entry for NCT00416624 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which quality-of-life assessment is the first listed.
NCT00416624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00416624 about?
NCT00416624 is a clinical study titled "Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy". RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer. PURPOSE: This randomized clinical trial is studying four different schedules of epoetin alfa or darbepoetin alfa to compare how...
What is the current status of trial NCT00416624?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2007-05. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00416624?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), fatigue assessment and management (PROCEDURE), darbepoetin alfa (DRUG), epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00416624?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.